Tech Company Financing Transactions

KAI Pharmaceuticals Funding Round

KAI Pharmaceuticals closed a $35 million Series B investment round on 5/2/2006. Investors included Aberdare Ventures, Investor Growth Capital and Delphi Ventures.

Transaction Overview

Company Information

Company Status

Acquired or Merged

Industry

Biopharmaceutical

Mailing Address

270 Littlefield Avenue
South San Francisco, CA 94080
USA

Phone

(650) 244-1100

Website

www.kaipharmaceuticals.com

Email Address

[email protected]

Overview

KAI Pharmaceuticals is a biology-based product-driven pharmaceutical company developing a new class of therapeutics targeting cell-signaling enzymes that affect numerous disease pathways. The company is leveraging its leadership position in protein kinase C (PKC), an important and validated family of kinases, to rapidly advance product candidates into human clinical trials.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Steven James

        

Chief Medical Officer

Gregory Bell

        

VP - Product Management

Susan Wilson

        

VP - R & D

Randolph Johnson

        

Browse more venture capital transactions:

Prev: 5/2/2006: Sphere Source venture capital transaction
Next: 5/3/2006: LeisureLink venture capital transaction

Share this article

About Database of VC Transactions

We do our best to document funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary